Get the Stockscreener App
3.41
5.01%
-0.18
After Hours:
3.43
0.02
+0.59%
Arbutus Biopharma Corp stock is traded at $3.41, with a volume of 1.13M.
It is down -5.01% in the last 24 hours and up +4.28% over the past month.
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
See More
Previous Close:
$3.59
Open:
$3.57
24h Volume:
1.13M
Relative Volume:
1.39
Market Cap:
$643.75M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.75
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+3.33%
1M Performance:
+4.28%
6M Performance:
-5.80%
1Y Performance:
+38.06%
1-Day Range:
$3.41
$3.615
1-Week Range:
$3.17
$3.615
52-Week Range:
$2.30
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.41 | 643.75M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Arbutus Biopharma Corp (ABUS) Stock: A Look at the Monthly Trend - The News Heater
Jefferies analysts upgrades a Buy rating for Arbutus Biopharma Corp (ABUS) - Knox Daily
Arbutus Biopharma Corp (ABUS) expanding its growth trajectory ahead - SETE News
Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus.com
JPMorgan Chase & Co. Increases Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Ballentine Partners LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp. to Host Earnings Call - ACCESS Newswire
Arbutus Biopharma (NASDAQ:ABUS) Receives “Buy” Rating from HC Wainwright - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 - MyChesCo
Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’ - Insider Monkey
Barclays PLC Purchases 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Cramer's Lightning Round: Arbutus Biopharma is 'the ultimate spec' - MSN
Arbutus Provides 2025 Corporate and Financial Update - GlobeNewswire
Jane Street Group LLC Has $258,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Principal Financial Group Inc. Sells 12,352 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development (NASDAQ:ABUS) - Seeking Alpha
Geode Capital Management LLC Buys 135,442 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Barclays PLC Acquires 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
State Street Corp Increases Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
State Street Corp Purchases 1,472,652 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Position Boosted by XTX Topco Ltd - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Charles Schwab Investment Management Inc. Grows Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Charles Schwab Investment Management Inc. Purchases 831,663 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Large Shareholder Urges Warminster-based Arbutus to Seek Partners Instead of Selling More Stock - MSN
Intech Investment Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Here’s Why Arbutus (ABUS) Surged in Q3 - Yahoo Finance
Arbutus Biopharma's SWOT analysis: focus on CHB treatment drives stock outlook - Investing.com
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - The Bakersfield Californian
Arbutus Biopharma's HBV Trial Hits 50% Cure Rate; Major Investor Urges Strategic Partnership - StockTitan
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma (STU:I9DN) 9-Day RSI : 39.19 (As of Dec. 01, 2024) - GuruFocus.com
Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - Yahoo Finance
Arbutus Biopharma (FRA:I9DN) Price-to-Operating-Cash-Flow : (As of Nov. 25, 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (STU:I9DN) Long-Term Debt & Capital Lease Obligation : €0.88 Mil (As of Sep. 2024) - GuruFocus.com
Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat
HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
Arbutus Biopharma to Showcase Innovations at Jefferies London Healthcare Conference - MyChesCo
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):